

Adult CIRB - Early Phase Emphasis Meeting Agenda

February 3, 2026

I Continuing Review

10005, A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma (Version Date 03/05/25)

II Continuing Review

10401, A Phase 0 window-of-opportunity pharmacodynamic trial of triapine (NSC# 663249) in uterine corpus serous adenocarcinoma (Version Date 05/19/25)

III Continuing Review

10637, A Phase 2 Study of Venetoclax in Relapsed Classic or Variant Hairy Cell Leukemia (Version Date 10/20/25)

IV Continuing Review

EAY191-N4, Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial (Version Date 10/29/25)

V Continuing Review

10464, A Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer (Version Date 11/03/25)
